Pavan Bachireddy, M.D.
Department of Hematopoietic Biology & Malignancy, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Hematopoietic Biology and Malignancy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Scientific Director, Department of ECLIPSE (Evolution of Cancer, Leukemia and Immunity Post Stem cEll transplant), Division of Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Assistant Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
The Bachireddy laboratory leverages high dimensional data in blood cancers to deconvolute co-evolving cancer-immune interactions in the microenvironment that dictate patient immunotherapeutic outcomes. Integrated with functional genomic perturbations, such insights will transform our understanding of disease pathogenesis and nominate targets for developing next generation immunotherapies
Education & Training
Degree-Granting Education
| 2009 | Stanford University School of Medicine, Stanford, CA, USA, MD, Medicine |
| 2003 | Harvard University, Cambridge, MA, USA, AB, Biochemical Sciences |
Postgraduate Training
| 2012-2015 | Clinical Fellowship, Medical Oncology, Dana-Farber Cancer Institute, Harvard Cancer Center, Boston, MA |
| 2009-2012 | Clinical Residency, Internal Medicine, Brigham and Women's Hospital, Boston, MA |
| 2009-2015 | Clinical Fellowship, Medicine, Harvard Medical School,, Boston, MA |
Experience & Service
Academic Appointments
Instructor, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 2015 - 2021
Other Appointments/Responsibilities
Attending Physician in Medicine, Brigham & Women’s Hospital, Boston, MA, 2015 - 2021
Institutional Committee Activities
Co-Leader, Cancer Program Working Group on Immuno-Oncology, Broad Institute of MIT and Harvard, 2018 - 2019
Honors & Awards
| 2023 | Damon Runyon Clinical Investigator, Damon Runyon Cancer Research Foundation |
| 2023 | Andrew Sabin Family Fellow, Andrew Sabin Family Foundation |
| 2022 | ASCI's 2022 Young Physician-Scientist Awards (YPSAs), The American Society for Clinical Investigation |
| 2021 | CPRIT Scholar in Cancer Research, Cancer Prevention and Research Institute of Texas |
| 2021 | UT Rising STARs |
| 2019 | Clinical Fellow Scholar Award, American Society of Hematology |
| 2019 | Amy Strelzer Manasevits Scholar Award, Be The Match Foundation |
| 2019 | Junior Faculty Clinician Scientist Distinguished Young Investigator Research Award - Annual Immuno-Oncology Young Investigators’ Forum, Society for Immunotherapy of Cancer |
| 2019 | Award Finalist, Burroughs Wellcome Fund Career Award for Medical Scientists |
| 2019 | Abstract Achievement Award, American Society of Hematology |
| 2018 | Abstract Achievement Award, American Society of Hematology |
| 2015 | Young Investigator Award, American Society for Blood and Marrow Transplantation (awarded then returned because of receipt of DRCRF award below) |
| 2015 | Damon Runyon Cancer Research Foundation Physician-Scientist Award, Damon Runyon Cancer Research Foundation |
| 2015 | Young Investigator Award, Conquer Cancer Foundation and American Society of Clincial Oncology |
| 2014 | Young Investigator Travel Award, Society of Hematologic Oncology |
| 2012 | Abstract Achievement Award, American Society of Hematology |
| 2006 | Scholar-in-Training Award, American Association for Cancer Research |
| 2003 | Harvard College Scholarship, Harvard College |
| 1998 | Eagle Scout Award, Boy Scouts of America |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Penter L, Zhang Y, Savell A, Huang T, Cieri N, Thrash EM, Kim-Schulze S, Jhaveri A, Fu J, Ranasinghe S, Li S, Zhang W, Hathaway ES, Nazzaro M, Kim HT, Chen H, Thurin M, Rodig SJ, Severgnini M, Cibulskis C, Gabriel S, Livak KJ, Cutler C, Antin JH, Nikiforow S, Koreth J, Ho VT, Armand P, Ritz J, Streicher H, Neuberg D, Hodi FS, Gnjatic S, Soiffer RJ, Liu XS, Davids MS, Bachireddy P, Wu CJ. Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation. Blood 137(23):3212-3217, 2021. e-Pub 2021. PMID: 33720354.
- Hu Z, Leet DE, Allesøe RL, Oliveira G, Li S, Luoma AM, Liu J, Forman J, Huang T, Iorgulescu JB, Holden R, Sarkizova S, Gohil SH, Redd RA, Sun J, Elagina L, Giobbie-Hurder A, Zhang W, Peter L, Ciantra Z, Rodig S, Olive O, Shetty K, Pyrdol J, Uduman M, Lee PC, Bachireddy P, Buchbinder EI, Yoon CH, Neuberg D, Pentelute BL, Hacohen N, Livak KJ, Shukla SA, Olsen LR, Barouch DH, Wucherpfennig KW, Fritsch EF, Keskin DB, Wu CJ, Ott PA. Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nat Med 27(3):515-525, 2021. e-Pub 2021. PMID: 33479501.
- Bachireddy P, Ennis C, Nguyen VN, Gohil SH, Clement K, Shukla SA, Forman J, Barkas N, Freeman S, Bavli N, Elagina L, Leshchiner I, Mohammad AW, Mathewson ND, Keskin DB, Rassenti LZ, Kipps TJ, Brown JR, Getz G, Ho VT, Gnirke A, Neuberg D, Soiffer RJ, Ritz J, Alyea EP, Kharchenko PV, Wu CJ. Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect. Sci Transl Med 12(561), 2020. PMID: 32938797.
- Davids MS, Kim HT, Costello C, Herrera AF, Locke FL, Maegawa RO, Savell A, Mazzeo M, Anderson A, Boardman AP, Weber A, Avigan D, Chen YB, Nikiforow S, Ho VT, Cutler C, Alyea EP, Bachireddy P, Wu CJ, Ritz J, Streicher H, Ball ED, Bashey A, Soiffer RJ, Armand P. A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. Blood 135(24):2182-2191, 2020. PMID: 32478814.
- Sarkizova S, Klaeger S, Le PM, Li LW, Oliveira G, Keshishian H, Hartigan CR, Zhang W, Braun DA, Ligon KL, Bachireddy P, Zervantonakis IK, Rosenbluth JM, Ouspenskaia T, Law T, Justesen S, Stevens J, Lane WJ, Eisenhaure T, Lan Zhang G, Clauser KR, Hacohen N, Carr SA, Wu CJ, Keskin DB. A large peptidome dataset improves HLA class I epitope prediction across most of the human population. Nat Biotechnol 38(2):199-209, 2020. e-Pub 2019. PMID: 31844290.
- Ten Hacken E, Valentin R, Regis FFD, Sun J, Yin S, Werner L, Deng J, Gruber M, Wong J, Zheng M, Gill AL, Seiler M, Smith P, Thomas M, Buonamici S, Ghia EM, Kim E, Rassenti LZ, Burger JA, Kipps TJ, Meyerson ML, Bachireddy P, Wang L, Reed R, Neuberg D, Carrasco RD, Brooks AN, Letai A, Davids MS, Wu CJ. Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. JCI Insight 3(19), 2018. e-Pub 2018. PMID: 30282833.
- Shukla SA, Bachireddy P, Schilling B, Galonska C, Zhan Q, Bango C, Langer R, Lee PC, Gusenleitner D, Keskin DB, Babadi M, Mohammad A, Gnirke A, Clement K, Cartun ZJ, Van Allen EM, Miao D, Huang Y, Snyder A, Merghoub T, Wolchok JD, Garraway LA, Meissner A, Weber JS, Hacohen N, Neuberg D, Potts PR, Murphy GF, Lian CG, Schadendorf D, Hodi FS, Wu CJ. Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade. Cell 173(3):624-633.e8, 2018. e-Pub 2018. PMID: 29656892.
- Davids MS, Kim HT, Bachireddy P , Costello C, Liguori R, Savell A, Lukez AP, Avigan D, Chen YB, McSweeney P, LeBoeuf NR, Rooney MS, Bowden M, Zhou CW, Granter SR, Hornick JL, Rodig SJ, Hirakawa M, Severgnini M, Hodi FS, Wu CJ, Ho VT, Cutler C, Koreth J, Alyea EP, Antin JH, Armand P, Streicher H, Ball ED, Ritz J, Bashey A, Soiffer RJ, Leukemia and Lymphoma Society Blood Cancer Research Partnership. Ipilimumab for Patients with Relapse after Allogeneic Transplantation. N Engl J Med 375(2):143-53, 2016. PMID: 27410923.
- Bachireddy P, Wu CJ. Arresting the Inflammatory Drive of Chronic Lymphocytic Leukemia with Ibrutinib. Clin Cancer Res 22(7):1547-9, 2016. e-Pub 2016. PMID: 26847060.
- Bachireddy P, Burkhardt UE, Rajasagi M, Wu CJ. Haematological malignancies: at the forefront of immunotherapeutic innovation. Nat Rev Cancer 15(4):201-15, 2015. e-Pub 2015. PMID: 25786696.
- Bachireddy P, Hainz U, Rooney M, Pozdnyakova O, Aldridge J, Zhang W, Liao X, Hodi FS, O'Connell K, Haining WN, Goldstein NR, Canning CM, Soiffer RJ, Ritz J, Hacohen N, Alyea EP, Kim HT, Wu CJ. Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion. Blood 123(9):1412-21, 2014. e-Pub 2013. PMID: 24357730.
- Bachireddy P, Wu CJ. Understanding anti-leukemia responses to donor lymphocyte infusion. Oncoimmunology 3:e28187, 2014. e-Pub 2014. PMID: 25340010.
- Bachireddy P , Rakhra K, Felsher DW. Immunology in the clinic review series; focus on cancer: multiple roles for the immune system in oncogene addiction. Clin Exp Immunol 167(2):188-94, 2012. PMID: 22235994.
- Choi PS, van Riggelen J, Gentles AJ, Bachireddy P, Rakhra K, Adam SJ, Plevritis SK, Felsher DW. Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction. Proc Natl Acad Sci U S A 108(42):17432-7, 2011. e-Pub 2011. PMID: 21969595.
- Contag CH, Sikorski R, Negrin RS, Schmidt T, Fan AC, Bachireddy P, Felsher DW, Thorne SH. Definition of an enhanced immune cell therapy in mice that can target stem-like lymphoma cells. Cancer Res 70(23):9837-45, 2010. e-Pub 2010. PMID: 20935221.
- Bachireddy P , Tseng D, Horoschak M, Chang DT, Koong AC, Kapp DS, Tran PT. Orthovoltage intraoperative radiation therapy for pancreatic adenocarcinoma. Radiat Oncol 5:105, 2010. e-Pub 2010. PMID: 21059255.
- Rakhra K*, Bachireddy P*, Zabuawala T*, Zeiser R*, Xu L*, Kopelman A*, Fan AC*, Yang Q*, Braunstein L*, Crosby E*, Ryeom S*, Felsher DW*. CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell 18(5):485-98, 2010. e-Pub 2010. PMID: 21035406.
- Horoschak M, Tran PT, Bachireddy P , West RB, Mohler D, Beaulieu CF, Kapp DS, Donaldson SS. External beam radiation therapy enhances local control in pigmented villonodular synovitis. Int J Radiat Oncol Biol Phys 75(1):183-7, 2009. e-Pub 2009. PMID: 19211195.
- Fan AC, Goldrick MM, Ho J, Liang Y, Bachireddy P, Felsher DW. A quantitative PCR method to detect blood microRNAs associated with tumorigenesis in transgenic mice. Mol Cancer 7:74, 2008. e-Pub 2008. PMID: 18826639.
- Wu CH, van Riggelen J, Yetil A, Fan AC, Bachireddy P, Felsher DW. Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc Natl Acad Sci U S A 104(32):13028-33, 2007. e-Pub 2007. PMID: 17664422.
- Arvanitis C, Bendapudi PK, Bachireddy P , Felsher DW. Identifying critical signaling molecules for the treatment of cancer. Recent Results Cancer Res 172:5-24, 2007. PMID: 17607933.
- Giuriato S, Ryeom S, Fan AC, Bachireddy P, Lynch RC, Rioth MJ, van Riggelen J, Kopelman AM, Passegué E, Tang F, Folkman J, Felsher DW. Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch. Proc Natl Acad Sci U S A 103(44):16266-71, 2006. e-Pub 2006. PMID: 17056717.
- Bachireddy P , Bendapudi PK, Felsher DW. Getting at MYC through RAS. Clin Cancer Res 11(12):4278-81, 2005. PMID: 15958607.
- Lim DS, Lutucuta S, Bachireddy P, Youker K, Evans A, Entman M, Roberts R, Marian AJ. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation 103(6):789-91, 2001. PMID: 11171784.
Grant & Contract Support
| Title: | Elucidating human leukemia and T cell interactions within the tumor microenvironment |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| Title: | Coevolution of leukemia and immune cells during GvL response and resistance |
| Funding Source: | The National Marrow Donor Program (Be The Match) |
| Role: | Principal Investigator |
| Title: | Co-evolution of lymphoma and immune cells following neoantigen vaccination in patients with follicular lymphoma or chronic lymphocytic leukemia |
| Funding Source: | American Society of Hematology (ASH) |
| Role: | Principal Investigator |
| Title: | Deconvolving mechanisms of GvL sensitivity and resistance in myeloid malignancies |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Principal Investigator |
Patient Reviews
CV information above last modified April 29, 2024